Can DRL’s new product launches offset the slowdown in Revlimid sales ?
Dr Reddy's Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US business. The company launched 24 new products, with a pipeline of 100 products expected to offset slowing Revlimid sales. Analysts remain cautious, with (...)
Site référencé: The Economic Times
The Economic Times
India revises up base import price of gold and vegetable oils
16/10/2025
ETMarkets Smart Talk : Ambit Capital’s Nitin Bhasin explains how tier-2 and tier-3 cities are shaping India’s consumption (...)
16/10/2025
In US, journalists turn in access badges, exit Pentagon rather than agree to govt's new reporting rules
16/10/2025
US to invade Venezuela ? Trump admits CIA covert operations, hints at land missions
16/10/2025
Asian stocks rise after choppy day on Wall Street
16/10/2025
Portfolio Overhaul : MFs shift gears towards autos, consumer and insurance plays in September
16/10/2025
